<DOC>
	<DOCNO>NCT00960544</DOCNO>
	<brief_summary>The goal clinical research study find gene expression ( well often expression occurs ) patient breast cancer affect XelodaÂ® ( capecitabine ) clear ( passed urine ) body . The safety capecitabine also study .</brief_summary>
	<brief_title>Correlation Genomic Variation Enzymes Responsible Metabolism Capecitabine With Drug Metabolism</brief_title>
	<detailed_description>Capecitabine , PK Testing , DNA Analysis : Capecitabine design interfere growth cancer cell , may cause cell die . It clear body certain protein ( make DNA -- gene material cell ) . Some patient change protein increase decrease rate capecitabine clear body . Researchers use pharmacokinetic ( PK ) test DNA analysis learn capecitabine clear body . PK test measure amount drug body different time point . Information learn study may help researcher decide best dos capecitabine future patient breast cancer . Screening Visit : Before start treatment study , 2 teaspoon blood drawn routine test make sure able receive chemotherapy . This screen blood test help study doctor decide eligible take part study . Capecitabine Treatment : If find eligible take part study , give capecitabine mouth day choose start therapy . Your treat doctor prescribe capecitabine dose appropriate treat cancer . You choose start date , exclude weekend , need begin therapy morning day choose . You treatment capecitabine even participate study . PK Testing DNA Analysis : You blood draw ( 2 teaspoon time ) PK test DNA analysis capecitabine certain time throughout study . - For PK testing , blood drawn first dose capecitabine , 30 , 60 , 90 minute first dose , 2 , 6 , 8 , 10 hour first dose . - For DNA analysis , blood drawn receive first dose capecitabine . If dose change , PK blood test may need repeat . Length Study : You remain study 6 month , unless disease get bad , experience intolerable side effect , decide stop treatment capecitabine . This investigational study . Up 100 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Patients must pathologic cytologic diagnosis invasive carcinoma breast . 2 . Patients must give informed consent protocol participation . 3 . Age &gt; /= 18 year 4 . Patients must ECOG performance status &lt; /=2 . 5 . Patients must schedule receive capecitabine use BID dose strategy administer day 114 21day cycle . 6 . Patients must agree blood draw PK/PD sampling . 7 . Patients allow receive cytotoxic therapy combination capecitabine . 8 . Patients must require concurrent radiation , hormonal therapy receive protocol therapy 9 . Patients must active infection require use intravenous antibiotic . The use oral antibiotic prophylaxis allow . 10 . Prior study enrollment , woman childbearing potential ( WOCBP ) must advise importance avoid pregnancy trial participation potential risk factor unintentional pregnancy . In addition , men enrol study understand risk sexual partner childbearing potential . Both men woman practice effective method birth control receive capecitabine . 11 . Patients must recover grade &lt; 1 acute toxicity previous chemotherapy , radiation hormonal therapy adequate hematologic hepatic function : Granulocyte count &gt; /= 1,500/mcL ; Platelet count &gt; /= 100,000/mcL ; Bilirubin &lt; /= 1.5 x ULN ; AST and/or ALT &lt; /= 2 x ULN ; Alkaline phosphatase ( liver component , fractionate ) &lt; /= 2 x ULN ; Serum creatinine within normal limit . 1 . Untreated uncontrolled brain metastasis 2 . History prior therapy capecitabine 3 . Patient inability take absorb oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Capecitabine</keyword>
	<keyword>Xeloda</keyword>
	<keyword>Gene expression</keyword>
	<keyword>Pharmacokinetic testing</keyword>
	<keyword>PK sample</keyword>
	<keyword>DNA analysis</keyword>
</DOC>